HHS has issued a policy allowing licensed pharmacies and physicians to temporarily compound six experimental peptides, including BPC-157 and TB-500, without fear of federal enforcement. The move comes despite objections from FDA career scientists citing limited evidence on safety and efficacy. The change effectively lowers compliance friction for off-label peptide use while formal review pathways remain separate. For clinicians and developers, it highlights how regulatory discretion can rapidly alter market availability even before controlled, evidence-generating trials mature.